<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616887</url>
  </required_header>
  <id_info>
    <org_study_id>1460</org_study_id>
    <nct_id>NCT02616887</nct_id>
  </id_info>
  <brief_title>Study of Image-Guided SBRT for Vertebral Metastases</brief_title>
  <official_title>Phase II Study of Image-Guided Single Fraction SBRT With VMAT-FFF Technique for Vertebral Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the known efficacy of ablative single dose SBRT and VMAT technique in various solid
      tumors, investigators have designed this study to assess feasibility of SBRT in selected
      patients with spine metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, phase 2 study. The main objectives are to assess acute and late side
      effects of single fraction SBRT for selected patients with vertebral metastases and to study
      the local control of disease in treated sites.

      The schedule will be 1 fraction of 18 Gy delivered in one day with Volumetric Modulated Arc
      Therapy (VMAT) and Flattening filter-free (FFF) beams.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity of single fraction SBRT on spine metastases using CTCAE v.4</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local control of the treated lesions using Kaplan-Meyer statistical curves</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain control at treated sites after RT using CTCAE v.4</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control of the metastatic disease using Kaplan-Meyer statistical curves</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival of treated patients using Kaplan-Meyer statistical curves</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of local and pain control between patients operated on vertebra and non-operated patients using CTCAE v.4</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Vertebral Metastases</condition>
  <arm_group>
    <arm_group_label>Vertebral metastases</arm_group_label>
    <description>Selected patients with spine metastases are treated with ablative single dose SBRT and VMAT technique in various solid tumors .</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Single dose SBRT and VMAT technique</intervention_name>
    <description>One fraction of 18 Gy delivered in one day with VMAT and Flattening filter-free (FFF) beams.</description>
    <arm_group_label>Vertebral metastases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with spine metastases
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18years.

          -  WHO performance status ≤ 2 (ECOG - KPS).

          -  Histologically-proven of primary cancer disease.

          -  Metastatic disease in the spine, from C1 to Sacrum. A maximum number of 5 sites. Each
             of the separate sites may have a maximal involvement of 2 contiguous vertebral bodies.

          -  Epidural compression is eligible when there is at least 3 mm gap between the spinal
             cord and the edge of the epidural lesion, unless patient underwent decompression
             surgery.

          -  A paraspinal mass ≤ 5 cm.

          -  Minimal residual tumor after surgery

          -  Metastases in other district of the body are allowed.

          -  Informed consent.

        Exclusion Criteria:

          -  &gt; 50% loss of vertebral body height.

          -  Prior radiation to the interested spine.

          -  Patients for whom an MRI of the spine is medically contraindicated.

          -  Patients allergic to contrast used in MRIs or CT scans or who cannot be premedicated
             for the use of contrast.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ciro Franzese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ciro Franzese, MD</last_name>
    <phone>+390282247454</phone>
    <email>ciro.franzese@humanitas.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciro Franzese, MD</last_name>
      <phone>+390282247454</phone>
      <email>ciro.franzese@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Piera Navarria, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Costa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>November 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2015</study_first_posted>
  <last_update_submitted>November 27, 2015</last_update_submitted>
  <last_update_submitted_qc>November 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Clinico Humanitas</investigator_affiliation>
    <investigator_full_name>Michele Tedeschi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

